SCHEMBL6898546

SCHEMBL6898546

NC(C1CCCCC1)C(O)(c1ccccc1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.42
KEAP1 Q14145 1/20 0.42
NFE2L2 Q16236 1/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.42
KIF11 P52732 2/20 0.41
METAP2 P50579 3/20 0.40
METAP1 P53582 1/20 0.40
DPP8 Q6V1X1 2/20 0.40
DPP4 P27487 1/20 0.40
DPP9 Q86TI2 1/20 0.40
DPP7 Q9UHL4 1/20 0.40
KCNA5 P22460 1/20 0.38
CYP2D6 P10635 3/20 0.38
CHRM2 P08172 2/20 0.38
CHRM1 P11229 2/20 0.38
CHRM3 P20309 2/20 0.38
KCNH2 Q12809 2/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6899688 1.00 IDO1 (0.42) IDO1KEAP1NFE2L2KDM4ELMNA
SCHEMBL6898544 1.00 IDO1 (0.42) IDO1KEAP1NFE2L2KDM4ELMNA
Hydrochloric Acid SCHEMBL6898738 0.98 IDO1 (0.44) IDO1KEAP1NFE2L2KDM4ELMNA
Hydrochloric Acid SCHEMBL6898731 0.98 IDO1 (0.44) IDO1KEAP1NFE2L2KDM4ELMNA
SCHEMBL6896239 0.81 GABBR2 (0.45) KDM4ELMNAMAPK1KIF11METAP2
SCHEMBL6896230 0.81 GABBR2 (0.45) KDM4ELMNAMAPK1KIF11METAP2
SCHEMBL6897515 0.79 SLC6A2 (0.47) LMNAMEN1KMT2A
SCHEMBL6896284 0.79 SLC6A2 (0.47) LMNAMEN1KMT2A
SCHEMBL6898442 0.76 METAP2 (0.44) KDM4EKIF11METAP2METAP1DPP8
SCHEMBL6898450 0.76 METAP2 (0.44) KDM4EKIF11METAP2METAP1DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1317461-B1 4-CYCLOHEXYL-1,3,2-OXAZABOROLIDINE CHIRAL ACCESSORIES SCHERING CORP (US) 2004-11-03 EP disclosed
EP-1317461-A1 4-CYCLOHEXYL-1,3,2-OXAZABOROLIDINE CHIRAL ACCESSORIES SCHERING CORPORATION (US) 2003-06-11 EP disclosed
US-6509472-B2 For use in enantioselective reduction of prochiral ketones to chiral secondary alcohols SCHERING CORPORATION 2003-01-21 US disclosed
US-20020038053-A1 For use in enantioselective reduction of prochiral ketones to chiral secondary alcohols SCHERING CORPORATION 2002-03-28 US disclosed
WO-2002022623-A1 4-CYCLOHEXYL-1,3,2-OXAZABOROLIDINE CHIRAL ACCESSORIES SCHERING CORPORATION (US) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020038053-A1 For use in enantioselective reduction of prochiral ketones to chiral secondary alcohols ADH5, ADH1A, ADH1C IDO1 2531/4885KEAP1 2794/4885NFE2L2 2793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.